We are live on
!
Find out more
GENB
Generate Biomedicines
GENB
GENB
57 hedge funds and large institutions have $1.16B invested in Generate Biomedicines in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
57
Holding in Top 10
4
Calls
$157K
Puts
–
Top Buyers
| 1 | +$765M | |
| 2 | +$51.5M | |
| 3 | +$48.9M | |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$43.9M |
| 5 |
JP Morgan Chase
New York
|
+$36M |
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIA
51
FNY Investment Advisers
New York
| $37K |
|
|||
52
Citigroup
New York
| $28.1K |
|
|||
|
VGA
53
Vanguard Global Advisers
Malvern,
Pennsylvania
| $15.3K |
|
|||
54
Wells Fargo
San Francisco,
California
| $15K |
|
|||
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K |
|
|||
|
AW
56
Avion Wealth
The Woodlands,
Texas
| $1K |
|
|||
|
TRCT
57
Tower Research Capital (TRC)
New York
| $12 |
|